Business Context and Reporting Period
This Form 8-K is a Current Report filed by Tivic Health Systems, Inc. (Trading Symbol: TIVC) on March 9, 2026, with the earliest event reported on March 9, 2026. The registrant is an emerging growth company incorporated in Delaware. The filing details the entry into material definitive agreements regarding new facility leases by its wholly-owned subsidiary, Velocity Bioworks, Inc. (VBI), located in San Antonio, Texas.
Key Financial Metrics and Lease Obligations
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines specific long-term lease commitments entered into by VBI:
- Microbial Building Lease: 8,024 sq. ft. facility. Initial term of 8 years. Aggregate base rent of approximately $5.34 million. Monthly base rent starts at ~$22,605.
- Mammalian Building Lease: 20,144 sq. ft. facility. Term of 102 months (effective Jan 1, 2026). Aggregate base rent of approximately $6.29 million. Monthly base rent starts at ~$55,030.
- Office Sublease: 8,122 sq. ft. office space (new principal executive office). Term of 110 months. Monthly base rent starts at ~$31,045 with ~3.0% annual increases.
- Additional Costs: VBI is responsible for operating expenses, taxes, and utilities based on ratable percentages for all three facilities.
Material Changes and Strategic Options
The primary material change is the expansion of physical infrastructure and the assumption of significant fixed lease liabilities. Key strategic options include:
- Extension Option: A one-time option to extend the Microbial Building Lease for an additional 5 years.
- Purchase Option: An exclusive option to purchase the Microbial Building and Property for $12.5 million at any time during the first 24 months of the initial lease term.
- Relocation: The Office Sublease establishes a new principal executive office location.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance regarding revenue or earnings. The primary risks and contingencies identified are:
- Fixed Obligations: The company has committed to over $11.6 million in aggregate base rent across the two primary building leases, plus variable operating costs.
- Termination Clauses: All leases are subject to earlier termination by the parties pursuant to their specific terms.
- Sublease Dependency: The Office Sublease is subject to the terms of the master lease between the landlord (TPB) and the sublessor (TRTF).
Investor Verification Checklist
- Verify the company's current cash position and liquidity to support the immediate and future rent payments totaling over $11.6 million in base rent.
- Confirm the operational readiness of the new facilities (Microbial and Mammalian buildings) to generate revenue commensurate with the new fixed costs.
- Review the specific termination clauses in the lease agreements to understand potential exit costs or liabilities.
- Assess the strategic rationale for the $12.5 million purchase option on the Microbial Building relative to the company's capital allocation strategy.